Back to search
FDAFDA · Food and drugs·Recall number D-0491-2017

glipiZIDE Extended-Release Tablets, 5 mg, 1000 count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 0378-0342-10

Published March 8, 2017 · Recall initiated: January 19, 2017

Summary

FDA records drug Class II recall D-0491-2017, published March 8, 2017 and initiated January 19, 2017. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 1338 bottles; Lot: Batch # 3074621, June 2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Foreign Tablets/Capsules; bottles of Glipizide 5 mg tablets may contain Glipizide 10 mg tablets

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Nationwide
Lot
Batch # 3074621, June 2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was glipiZIDE Extended-Release Tablets, 5 mg, 1000 count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 0378-0342-10 recalled?

Yes. FDA published recall D-0491-2017 on March 8, 2017. Reported hazard: Presence of Foreign Tablets/Capsules; bottles of Glipizide 5 mg tablets may contain Glipizide 10 mg tablets

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail